Suzhou Suncadia Biopharmaceuticals Co. Ltd. and Jiangsu Hengrui Medicine Co. Ltd. have synthesized isoquinolone compounds acting as phosphodiesterase PDE3A and/or PDE4 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), sepsis, nephritis, diabetes, allergic rhinitis, allergic conjunctivitis and rheumatic diseases.
Medshine Discovery Inc. has disclosed derivatives of a six-membered heteroaromatic urea ring acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of diabetic and hypertensive nephropathy.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has patented poly(ADP-ribose) polymerase (PARP) inhibitors, particularly PARP-1, reported to be useful for the treatment of cancer.
Kayothera Inc. and Princeton University have identified aldehyde dehydrogenase (ALDH) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes and metabolic disease, as well as for male contraception.
Gilead Sciences Inc. has synthesized carboxy-benzimidazoles acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of arthritis, diabetes, eating disorders, macular degeneration, myocardial infarction, nonalcoholic steatohepatitis, sleep apnea and Parkinson's disease, among others.
Essa Pharma Inc. has divulged androgen receptor antagonists reported to be useful for the treatment of metastatic castration-resistant prostate cancer.
Nihon Medi-Physics Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising a peptide-modified antibody targeting B-lymphocyte antigen CD20 covalently linked to a radionuclide-chelating agent through a linker reported to be useful for the diagnosis and treatment of cancer.
RSS